

Based on Form PTO-1449 (1/04)		ATTY. DOCKET NO. 57637/1380		SERIAL NO. 10/828,925	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANTS Cappeletti et al.			
		FILING DATE April 20, 2004		GROUP ART UNIT 1616 1618	

OIPE JCSS
JUL 29 2005
RECEIVED TRADEMARK OFFICE



U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
[Signature]	AA	5,620,955	4/15/97	Knight et al.		
	AB	5,534,497	6/9/96	Verbruggen		
	AC	5,620,959	4/15/97	Leban et al.		
	AD	5,369,094	11/29/94	Schally et al.		
	AE	5,244,883	9/14/93	Cai et al.		
	AF	5,217,955	6/8/93	Bogden et al.		
	AG	6,200,546	3/13/01	Hoffman et al.		
	AH	5,686,410	11/11/97	Albert et al.		
	AI	5,428,019	6/27/95	Edwards et al.		
	AJ	5,428,018	6/27/95	Edwards et al.		
	AK	4,988,496	1/29/91	Srinivasan et al.		
	AL	5,834,433	11/10/98	Krstenansky		
	AM	4,885,363	12/5/89	Tweedle		
	AN	6,075,121	6/13/00	Simon et al.		
	AO	5,965,695	10/12/99	Simon et al.		
	AP	5,410,018	4/25/95	Spindel et al.		
	AQ	5,244,883	9/14/93	Cai et al.		
[Signature]	AR	5,068,222	11/26/91	Camble et al.		
	AS	2003/0224998	12/4/03	Reubi et al.		
AT						

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	CLASS	SUB-CLASS	TRANSLATION	
[Signature]	BA	WO91/01144	2/7/91	Albert et al.			
	BB	WO96/03427	2/8/96	Pollak et al.			
	BC						

OTHER PUBLICATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)	
[Signature]	CA GIBLIN et al. (1998), Proc. Natl. Aca. Sci., USA, Vol. 95, pp. 12814-12818.
[Signature]	CB WALSH et al., Western Journal of Medicine, Vol. 155, pp. 152-163, 1991.
[Signature]	CC HEPPELER et al., Receptor Targeting for Tumor Localization and Therapy with Radiopeptides. Current Medicinal Chemistry 2000, 7:971-994.
[Signature]	CD SETHI et al., Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo, Cancer Res. 1992 May 1;52(9 Suppl):2737s-2742s.



EXAMINER [Signature]	DATE CONSIDERED 9/27/07
-------------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	CE	HALMOS, T., WITTLIFF, J.L., and SCHALLY, A.V., Characterization of bombesin/gastrin releasing peptide receptors on human breast cancer and their Relationship to steroid receptor expression, Cancer Research 55:280-287, 1995.
	CF	KELLY, K., KANE, M.A., and BUNN, P.A., "Growth factors in lung cancer: Possible etiologic role and clinical target", Medical and Pediatric Oncology 19:449-458, 1991.
	CG	JENSEN, R.T., MROZINSKI, J.E., and COY, D.H., "Bombesin receptor antagonists: Different classes and cellular basis of action" Recent Results in Cancer Research 129:87-113. <i>(date not available)</i>
	CH	REILE, H., ARMATIS, P.E., and SCHALLY, A.V., Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells, Prostate, 1994 Jul;25(1):29-38.
	CI	SCHUTTE, J., and SEEGER, S., "Bombesin antagonists: Experimental and clinical results", Recent Results in Cancer Research 129:115-129, 1993
	CJ	WALSH, J.H., KARNES, W.E., CUTTITA, F., and WALKER, A., "Autocrine growth factors and solid tumor malignancy", Western Journal of Medicine 155: 152-163, 1991
	CK	LEBAN, et al., Potent gastrin-releasing peptide (GRP) antagonists derived from GRP (19-27) with a C-terminal DPro psi [CH2NH]Phe-NH2 and N-terminal aromatic residues, J Med Chem. 1994 Feb 18;37(4):439-45.
	CL	LI, et al.; In-Vivo and In-Vitro Characterization of a Rh-105-Tetrathiamacrocycle Conjugate of a Bombesin Analogue, Proceedings of the 43rd Annual Meeting, vol. 37, No. 5, May 1996 Supplement, p. 61.
	CM	ZHU, et al.; Binding, internalization, and processing of bombesin by rat pancreatic acini, Bombesin Binding and Internalization, 1991, pp. G57-G64.
	CN	MOODY, et al.; BW1023U90: A new GRP Receptor Antagonist for Small-Cell Lung Cancer Cells, Peptides vol. 17, No. 8, pp. 1337-1343, 1996.
CO	MOODY, et al.; A GRP Receptor Antagonist Which Inhibits Small-Cell Lung Cancer Growth; Life Sciences, vol. 56, No. 7, pp. 521-529, 1995.	
	CP	SEIFERT, et al.; No Carrier Added Preparations of '3+1' Mixed-ligand 99mTc Complexes, Appl. Radiat. Isot. Vol. 49, Nos. 1-2, pp. 5-11, 1998.
	CQ	SMITH, et al.; In Vivo and In Vitro Characterization of Novel Water-Soluble Dithio-Bisphosphine 99mTc Complexes, Nuclear Medicine & Biology, vol. 24, pp. 685-691, 1977.
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



9/27/07


	CR	COY et al., "Short Chain Pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic Acinar and swiss 3T3 cells display strong Antimitotic activity" J. Biol. Chem., vol. 264, No. 25, pp. 14691-14697, 1989.
	CS	THOMAS et al., Antitumoral Activity of Bombesin Analogues on Small Cell Lung Cancer Xenografts: Relationship with Bombesin Receptor Expression, Cancer Res. 1992 Sep 15;52(18):4872-7.
	CT	RADULOVIC et al., Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice, Acta Oncol. 1994;33(6):693-701.
	CU	QIN, et al., Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro, Cancer Res. 1994 Feb 15;54(4):1035-41.
	CV	QIN, et al., Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP, Int J Cancer. 1995 Oct 9;63(2):257-62.
	CW	CAI et al., Potent Bombesin antagonists with C-Terminal Leu-(CH2-N)-Tac-NH2 or its Derivatives, (1994) Proc. Natl. Acad. Sci., 91:12664-12668.
	CX	RADULOVIC, et al., Biological effects and receptor binding affinities of new pseudonapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi, Int J Pept Protein Res. 1991 Dec;38(6):593-600.
	CY	STALEY, et al., [Des-Met14]bombesin analogues function as small cell lung cancer bombesin receptor antagonists, Peptides. 1991 Jan-Feb;12(1):145-9.
	CZ	WANG et al., Desmethionine alkylamide bombesin analogues: a new class of bombesin receptor antagonists with potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells, Biochemistry. 1990 Jan 23;29(3):616-22.
	CAB	WANG, KNEZETIC, SCHALLY, POUR, ADRIAN; Bombesin May Stimulate Proliferation of Human Pancreatic Cancer Cells Through An Autocrine Pathway, Int. J. Cancer: 68, 528-534 (1996).
	CAC	YANO, PINSKI, GROOT, SCHALLY, Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines, Cancer Res. 1992 Aug 15;52(16):4545-7.
	CAD	KANE, AUGUAYO, PORTANOVA, ROSS, HOLLEY, KELLY, MILLER, Isolation of the bombesin/gastrin-releasing peptide receptor from human small cell lung carcinoma NCI-H345 cells, J Biol Chem. 1991 May 25;266(15):9486-93.
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



8/22/07

	CAE	SCHULLER, Receptor-mediated mitogenic signals and lung cancer, Cancer Cells. 1991 Dec;3(12):496-503.
	CAF	HALMOS et al., Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression, Cancer Res. 1995 Jan 15;55(2):280-7.
	CAG	HAJRI et al., Gastrin-releasing peptide: in vivo and in vitro growth effects on an acinar pancreatic carcinoma, Cancer Res. 1992 Jul 1;52(13):3726-32.
	CAH	FRITZBERG, et al., Radiolabeling of Antibodies for Targeted Diagnostics, Handbook of Targeted Delivery of Imaging Agents (ed) V.P. Torchilin, CRC Press, Boca Raton, Florida, Chapter 6, pp. 83-101, 1995.
	CAI	RADULOVIC, et al., The Binding of Bombesin and Somatostatin and Their Analogs to Human Colon Cancers, 1992.
	CAJ	John E. TAYLOR, Identification and Characterization Somatostatin (SRIF), Gastrin Releasing Peptide (GRP), and Neuromedin B (NMB) Receptors on Established Tumors and Tumor Cell Lines, 1993.
	CAK	BENYA, et al., Gastrin-releasing peptide receptor-induced internalization, down-regulation, desensitization, and growth: possible role for cyclic AMP, Mol Pharmacol. 1994 Aug;46(2):235-45.
	CAL	YANO, et al., Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice, Cancer. 1994 Feb 15;73(4):1229-38.
	CAM	KULL, Jr., et al., Conveyance of partial agonism/antagonism to bombesin/gastrin-releasing peptide analogues on Swiss 3T3 cells by a carboxyl-terminal leucine insertion, J Biol Chem. 1992 Oct 15;267(29):21132-8.
	CAN	HEINZ-ERIAN, et al., [D-Phe12]bombesin analogues: a new class of bombesin receptor antagonists, Am J Physiol. 1987 Mar;252(3 Pt 1):G439-42.
	CAO	HALMOS, et al., Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer, Cancer Lett. 1994 Sep 30;85(1):111-8.
	CAP	COY, et al., Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity, J Biol Chem. 1989 Sep 5;264(25):14691-7.
	CAQ	WOLL, et al., [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro, Proc Natl Acad Sci U S A. 1988 Mar;85(6):1859-63.
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

9/22/07


	CAR	WANG, et al., des-Met carboxyl-terminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists, or agonists, J Biol Chem. 1990 Sep 15;265(26):15695-703.
	CAS	VON SCHRENCK, et al., "Potent Bombesin Receptor Antagonists distinguish Receptor Subtypes", Amer. J. Physiol., vol. 259, pp. G468-G473, 1990.
	CAT	SINGH, et al., A novel bombesin receptor antagonist (2258U89), potently inhibits bombesin evoked release of gastrointestinal hormones from rats and dogs, in vitro and in vivo, Regul Pept. 1992 Jul 2;40(1):75-86.
	CAU	LEBAN, et al., Development of Potent Bombesin/Gastrin-Releasing Peptide antagonists Having a D-Pro-(CH ₂ NH)-Phe-NH ₂ C Terminus, Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1922-6.
	CAV	MAHMOUD, et al., "[Psi 13, 14] Bombesin Analogues Inhibit Growth of Small Cell Lung Cancer in Vitro and in Vivo", Cancer Res. 1991 Apr 1;51(7):1798-802.
	CAX	TROUTNER, David E., Chemical and Physical Properties of Radionuclides, Nucl. Med. Biol. vol.14, No. 3, pp. 171-176, 1987.
	CAY	VALLABHAJOSULA, et al., Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides, J Nucl Med. 1996 Jun;37(6):1016-22.
	CBA	GALI, et al., Synthesis, characterization, and labeling with 99mTc/188Re of peptide conjugates containing a dithia-bisphosphine chelating agent, Bioconjugate Chem. 2001 May-Jun;12(3):354-63.
	CBB	BIJSTERBOSCH, MK; Selective Drug Delivery by Means of Receptor-Mediated Endocytosis, The Quarterly Journal of Nuclear Medicine, vol. 39, No. 1, pp. 4-19, Mar. 1995.
	CBC	PARKER, David; Tumor Targeting with Radiolabelled Macrocyclic-Antibody Conjugates, Chemical Society Reviews, vol. 19, No. 3, Sep. 1990, pp. 271-291.
CBD	WILBUR, D. Scott; Radiohalogenation of Proteins: An Overview of Radionuclides, Labeling Methods, and Reagents for Conjugate Labeling, Bioconjugate Chem. 1992 Nov-Dec;3(6):433-70.	
CBE	SMYTHE, et al.; The Mechanism of Receptor-Mediated Endocytosis; Eur. J. Biochem. 202, pp. 689-699, 1991.	
CBF	WONG, et al.; Rhenium(V), and Technetium(V) Oxo Complexes of an N ₂ N's Peptide Chelator: Evidence of Inter-conversion between the Syn and Anti Conformations; Inorg. Chem., 1997, 36, pp. 5799-5808.	
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



9/27/07





	CBG	SCHUMBIGER, et al.; Vehicles, Chelators, and Radionuclides: Choosing the "Building Blocks" of an Effective Therapeutic Radioimmunoconjugate; Bioconjugate Chemistry, vol. 7, No. 2, pp. 165-179, Mar./Apr. 1996.
	CBH	MATTES, M.J.; Pharmacokinetics of Antibodies and their Radiolabels. In: Cancer Therapy with Radiolabelled Antibodies (ed) D.M. Goldenberg, CRC Press, Boca Raton, Florida, Chapter 8, pp. 89-99. <i>(date not available)</i>
	CBI	LI, et al.; Comparisons of Rh(III) Chloride Complexation with [14]aneNS, [14]aneN2S2 and [14]aneN4 Macrocycles in Aqueous Solution, Radiochemica Acta 75, pp. 83-95 (1996).
	CBJ	LISTER-JAMES, et al.; Pharmacokinetic considerations in the development of peptide-based imaging agents, The Quarterly Journal of Nuclear Medicine, vol. 41, No. 2, pp. 111-118. <i>(date not available)</i>
	CBK	LAMBERTS, S.W.J., REUBI, J.C., KRENNING, E.P.; Somatostatin and the Concept of Peptide Receptor Scintigraphy in Oncology, Seminars in Oncology, vol. 21, No. 5, Suppl. 13 (Oct.) 1994, pp. 1-5.
	CBL	HERMANSON; Bioconjugate Techniques, Academic Press, Functional Targets, Chapter 1, pp. 3-136 (1996).
	CBM	HOFFKEN, K.; Peptides in Oncology II, Somatostatin Analogues and Bombesin Antagonists (1993), Springer-Verlag, Berlin-Heidelberg, pp. 87-112.
	CBO	KRENNING, et al.; Essentials of Peptide Receptor Scintigraphy with Emphasis on the Somatostatin Analog Octreotide, Seminars in Oncology, vol. 21, No. 5, Suppl. 13 (Oct., 1994), pp. 6-14.
	CBP	ECKELMAN, William C., GIBSON, Raymond E., (1993) The Design of Site-Directed Radiopharmaceuticals for use in Drug Discovery, Nuclear Imaging in Drug Discovery, Development, and Approval (eds) H.D. Burns et al., Birkhauser Publ. Inc., Boston, Ma.
	CBQ	FISCHMAN, et al.; A ticket to ride: peptide radiopharmaceuticals, J Nucl Med. 1993 Dec;34(12):2253-63.
	CBR	DUNCAN et al.; Indium-111-Diethylenetriaminepentaacetic Acid-Octreotide is Delivered in Vivo to Pancreatic, Tumor Cell, Renal, and Hepatocyte Lysosomes, Cancer Res. 1997 Feb 15;57(4):659-71.
	CBS	ECKELMAN, William c.; Radiolabeling with technetium-99m to study high-capacity and lo-capacity biochemical systems, Eur J Nucl Med. 1995 Mar;22(3):249-63.
	CBT	DAVIS, et al.; Metabolic Stability and Tumor Inhibition of Bombesin/GRP Receptor Antagonists, Peptides. 1992 Mar-Apr;13(2):401-7.
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

9/27/07

	CBU	De JONG et al.; Yttrium-90 and indium-111 labeling, receptor binding and biodistribution of [DOTA0, d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy, Eur J Nucl Med. 1997 Apr;24(4):368-71.
	CBV	FRITZBERG et al.; Targeted proteins for diagnostic imaging: does chemistry make a difference?; J Nucl Med. 1992 Mar;33(3):394-7.
	CBW	CAI et al.; Pseudonona peptide Bombesin Antagonists Containing C-Terminal Trp or Tpi, Peptides, 1992 Mar-Apr;13(2):267-71.
	CBX	COY et al.; Probing peptide backbone function in bombesin. A reduced peptide bond analogue with potent and specific receptor antagonist activity, J Biol Chem. 1988 Apr 15;263(11):5056-60.
	CBY	Donald J. BUCHSBAUM; Cancer Therapy with Radiolabelled Antibodies; Pharmacokinetics of Antibodies and their Radiolabels; Experimental Radioimmunotherapy and Methods to Increase Therapeutic Efficacy; CRC Press, Boca Raton, Chapter 10, pp. 115-140, 1995.
	CCA	ZHU et al.; Binding, internalization, and processing of bombesin by rat pancreatic acini, Am J Physiol. 1991 Jul;261(1 Pt 1):G57-64.
	CCB	MULSHINE et al.; Autocrine growth factors as therapeutic targets in lung cancer, Chest. 1989 Jul;96(1 Suppl):31S-34S. Review.
	CCC	HOFFKEN, K.; Peptides in Oncology II, Somatostatin Analogues: Mechanisms of Action, (1994), Springer-Verlag, Berlin-Heidleberg, pp. 1-136.
	CCD	GALI, et al.; In Vitro and in Vivo Evaluation of 111In Labeled DOTA_8_Aoc_BBN[7_14]NH2 Conjugate for Specific Targeting of Tumors Expressing Gastrin Releasing Peptide (GRP) Receptors, 47 th Annual Meeting – Society of Nuclear Medicine, St. Louis, MO, J. Nucl. Med., 41(5), 119P, #471, 2000.
CCE	GALI, et al.; Influence of the Radiometal on the In Vivo Pharmacokinetic Properties of a Radiometal-labeled DOTA-Conjugated Peptide, 222 nd American Chemical Society National Meeting, Chicago, IL, August, 2001 (Accepted)	
CCF	HOFFMAN, et al.; Development and Characterization of a Receptor-Avid 111In-Labeled Peptide for Site Specific Targeting of Colon Cancer, 92 nd Annual Meeting of the American Association for Cancer Research, New Orleans, LA, Proceedings of the American Association for Cancer Research, Vol. 42, 139, #746, march 2001.	
CCG	HOFFMAN, et al.; Rh-105 Bombesin Analogs: Selective In Vivo Targeting of Prostate Cancer with a therapeutic Radionuclide, 45 th Annual Meeting-Society of Nuclear Medicine, June 1998;J.Nucl. Med., 39(5), #982, 222P.	
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		






9/27/07

	CCH	HOFFMAN, et al.; Uptake in retention of a Rh-105 Labeled Bombesin Analogue in GRP Receptor Expressing Neoplasms: An In-Vitro Study, 44 th Annual Meeting – Society of Nuclear Medicine, June, 1997; J. Nucl. Med., 38(5), #808, 188P, 1997.
	CCI	HOFFMAN, et al.; Synthesis and Characterization of Rh-105 Labeled Bombesin Analogues: Enhancement of GRP Receptor Binding Affinity Utilizing Aliphatic Carbon Chain Linkers, 12 th International Symposium on Radiopharmaceutical Chemistry, June, 1997; (abstract)
	CCJ	HOFFMAN, et al.; Specific Uptake and retention of Rh-105 Labeled Bombesin Analogues in GRP-Receptor Expressing Cells, European Society of Nuclear Medicine, August, 1997; Eur. J. Nucl. Med., 24(8), 901, 1997.
	CCK	HOFFMAN et al.; Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells, Nucl Med Biol. 2001 Jul;28(5):527-39.
	CCL	HOFFMAN et al.; Targeting Small Cell Lung Cancer Using Iodinated Peptide Analogs, 11 th International Symposium on Radiopharmaceutical Chemistry, August, 1995; J. Label. Comp'd Radiopharm., 37:321-323, 1995.
	CCM	HOFFMAN et al.; Iodinated Bombesin Analogs: Effect of N-Terminal Chain Iodine Attachment on BBN/GRP Receptor Binding, 43 rd Annual Meeting – Society of Nuclear Medicine, May, 1996; J. Nucl. Med., 37(5), p185P, #850, 1996.
	CCN	HOFFMAN et al.; Accumulation and Retention of 99mTc-RP591 by GRP Receptor Expressing Tumors in SCID Mice, Congress of the European Association of Nuclear Medicine, Barcelona, Spain, Eur. J. Nucl. Med., 26(9), 1157, #PS-416, September, 1999.
	CCO	HOFFMAN et al.; Accumulation and Retention of 99mTc-RP527 by GRP Receptor Expressing Tumors in SCID Mice, 46 th Annual Meeting – Society of Nuclear Medicine, June 9, 1999, Los Angeles, CA, J. Nucl. Med., 40(5), 104P, #419, 1999.
	CCP	HOFFMAN et al.; 111In/90Y Radiolabelled Peptides for Targeting Prostate Cancer; A Matched Pair Gastrin Releasing Peptide (GRP) Receptor Localizing Radiopharmaceutical, 48 th Annual Meeting – Society of Nuclear Medicine, #1149, Toronto, Ontario, Canada, June 2001. (Accepted)
	CCQ	HOFFMAN et al.; Vitro and in Vivo Evaluation of 111In/90Y Radiolabelled Peptides for Specific Targeting of Tumors Expressing Gastrin Releasing Peptide (GRP) Receptors, 92 nd Annual Meeting of the American Association for Cancer Research, New Orleans, LA. Proceedings of the American Association for Cancer Research, Vol. 42, 773, #4148, March 2001.
EXAMINER	DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		






9/27/07

	CCR	HOFFMAN et al.; Development of a Diagnostic Radiopharmaceutical for Visualization of Primary and Metastatic Breast Cancer, 48 th Annual Meeting – Society of Nuclear Medicine, #1149, Toronto, Ontario, Canada, June 2001, J. Nucl. Med., 45(5):245P, #1067.
	CCT	HOFFMAN et al.; Targeting Gastrin Releasing Peptide (GRP-R) Expression in Prostate and Pancreatic Cancer Using Radiolabelled GRP Agonist Peptide Vectors, American Association for Cancer Research Annual Meeting, San Francisco, CA, Proceedings of the American Association for Cancer Research, Vol. 41, 529, #3374, April 2000.
	CCU	HOFFMAN T.J., SMITH, C.J., SIMPSON, S.D., SIEKMAN, G., HIGGINBOTHAM, C., JIMINEZ, H., ESHIMA, D., THORNBAC, J.R. and VOLKERT, W.A.; Optimizing Pharmacokinetics of Tc-99m-GRP Receptor Targeting Peptides Using Multi-Amino Acid Linking groups, 47 th Annual Meeting – Society of Nuclear Medicine, St. Louis, MO, J. Nucl. Med., 41(5), 228, #1013, 2000.
	CCV	JURRISON, S., CUTLER, C., HU, F., HOFFMAN, T.J., VOLKERT, W.A.; DOTA Bombesin Complexes with Sm-153 and NCA PM-149, The International Chemical Congress of Pacific Basin Societies, Pacificchem 2000, Honolulu, HI, December, 2000.
	CCW	KARA, S.R., SCHIBLI, R., GALI, H., KATTI, K.V., HOFFMAN, T.J., HIGGINBOTHAM, C., SIEKMAN, G., VOLKERT, W.A.; 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent, Bioconjug Chem. 1999 Mar-Apr;10(2):254-60.
	CCX	KATTI, K.V., GALI, H., SCHIBLI, R., HOFFMAN, T.J., and VOLKERT, W.A.; 99mTc/Re Coordination Chemistry and Biomolecule Conjugation Strategy of a Novel Water Soluble Phosphine-Based Bifunctional Chelating Agent, In Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine (5), Ed by M. Nicolini and U. Mazzi, Servizi Grafici Editoriali, Padova, pp. 93-100, 1999.
	CCY	KOTHARI, K.K. KATTI, K.V., PRABHU, K.R., GALI, H., PILLARSETTY, N.K., HOFFMAN, T.J., OWEN, N.K., and VOLKERT, W.A.; Development of a Diamido-Diphosphine (N2P2)-BFCA for Labeling Cancer Seeking Peptides via the 99mTc(1)(CO)3(H2O)3 Intermediate, 47 th Annual Meeting – Society of Nuclear Medicine, St. Louis, MO, J. Nucl. Med., 41(5), 244P, #1079, 2000.
	CCZ	LI, et al.; Development of an in vitro model for assessing the in vivo stability of lanthanide chelates, Nucl Med Biol. 2001 Feb;28(2):145-54.
	CDB	QIN, et al.; Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors, J Cancer Res Clin Oncol., 1994; 120(9): 519-28.
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



9/27/07

	CDC	SCHIBLI, R., KARRA, S.R., GALI, H., KATTI, K.V., HIGGINBOTHAM, C., SMITH, C.J., HOFFMAN, T.J., and VOLKERT, W.A.; Conjugation of Small Biomolecules and Peptides with Water-Soluble Dithio-Bis-Hydroxymethylphosphine Ligands, Center Radiological Research, University of Missouri, Columbia, MO, USA. Book of Abstracts, 215 th ACS National Meeting, Dallas, March 29-April 2, 1998, NUCL-062.
	CDD	SCHIBLI, R., KARRA, S.R., KATTI, K.V., GALI, H., HIGGINBOTHAM, C., SIEKMAN, G., HOFFMAN, T.J., and VOLKERT, W.A.; A Tc-99m-Dithia-Di(Bis-Hydroxy-methylene) Phosphine Conjugate of Bombesin: In Vitro and In Vivo Studies, 45 th Annual Meeting – Society of Nuclear Medicine, May 1998; J. Nucl. Med., 39(5), 225P, #997.
	CDE	SMITH, C.J., HOFFMAN, T.J., GALI, H., HAYES, D.L., OWEN, N.K., SIEKMAN, G.L. and VOLKERT, W.A.; Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH ₂ : A New Gastrin Releasing Peptide Receptor (GRPr) Targeting Radiopharmaceutical, J. Labeled Compounds and Radiopharmaceutical, J. Labeled Cpd. Radipharm., 44 (51):5706-5708, 2001.
	CDF	VOLKERT, W.A.; Rh-105 Bombesin Analogs: Selective In Vivo Targeting of Prostate Cancer with a Therapeutic Radionuclide, 45 th Annual Meeting – Society of Nuclear Medicine, June 1998; J. Nucl. Med., 39(5):222P, #59, 1998.
	CDG	VOLKERT, W.A., and HOFFMAN, T.J., Design and Development of Receptor-avid Peptide Conjugates for In Vivo Targeting of Cancer, Part of the SPIE Conference of Molecular Imaging: Reporters-Dyes, Markers and Instrumentation, SPIE Vol. 3600:86-98, January 1999.
	CDH	VOLKERT, W.A., GALI, H., HOFFMAN, T.J., OWEN, N.K., SIEMAN, G.L., and SMITH, C.J.; In-111/90Y Labeled GRP Analogs: A Structure-Activity Relationship, The International Chemical Congress of Pacific Basin Societies, Pacificchem 2000, Honolulu, HI, December, 2000.
	CDJ	FOSTER, B., and VOLKERT, W.A.; In-111/90Y Radiolabelled Peptides for targeting Prostate Cancer; A Matched Pair Gastrin releasing Peptide (GRP) Receptor Localizing Radiopharmaceutical, 48 th Annual Meeting – Society of Nuclear Medicine, Toronto, Ontario, Canada, June 2001. (Accepted)
EXAMINER 		DATE CONSIDERED 9/27/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

filed 8/23/06



PTO/SB/08a (08-03)


Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10828925
	Filing Date		2004-04-20
	First Named Inventor	Cappelletti	
	Art Unit	1616 1618	
	Examiner Name	to be assigned D. Jones	
	Attorney Docket Number	57637-1380	

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1	6307017		2001-10-23	Coy et al.		
	2	5084555		1992-01-28	Coy et al.		
	3	5217955		1993-06-08	Bogden et al.		
	4	5833985		1998-11-10	Ball et al.		
	5	5981504		1999-11-09	Buchsbaum et al.		
	6	6921526		2005-07-26	Hoffman et al.		
	7	6866837		2005-03-15	Reubi et al.		
	8	6191290		2001-02-20	Safavy		
If you wish to add additional U.S. Patent citation information please click the Add button.							Add



8/27/07

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10828925
Filing Date	2004-04-20
First Named Inventor	Cappelletti
Art Unit	1616 11618
Examiner Name	to be assigned D. Jones
Attorney Docket Number	57637-1380

U.S. PATENT APPLICATION PUBLICATIONS

[Remove](#)

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20030050436		2003-03-13	Coy et al.	
	2	20020176819		2002-11-28	Hoffman et al.	
	3	20050163710		2005-07-28	Hoffman et al.	
	4	20060067886		2006-03-30	Hoffman et al.	
	5	20050171014		2005-08-04	Tarasova et al.	

cbss/
swb

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0489089	EP		1996-06-19			<input type="checkbox"/>
	2	0438519	EP		1998-05-06			<input type="checkbox"/>
	3	0309297	EP		1989-03-29			<input checked="" type="checkbox"/>

8/27/07

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10828925
Filing Date		2004-04-20
First Named Inventor	Cappelletti	
Art Unit	1016 1618	
Examiner Name	to be assigned D. Jones	
Attorney Docket Number	57637-1380	



4	91/02746	WO		1991-03-07			<input type="checkbox"/>
5	90/03980	WO		1990-04-19			<input type="checkbox"/>
6	89/02897	WO		1989-04-06			<input type="checkbox"/>
7	0436005	EP		1995-03-29			<input type="checkbox"/>
8	95/24220	WO		1995-09-14			<input type="checkbox"/>
9	0749325	EP		2002-06-12			<input type="checkbox"/>
10	98/47524	WO		1998-10-29			<input type="checkbox"/>
11	99/62563	WO		1999-12-09			<input type="checkbox"/>
12	1001977	EP		2005-10-05			<input type="checkbox"/>
13	00/50059	WO		2000-08-31			<input type="checkbox"/>
14	03/72754	WO		2003-09-04			<input type="checkbox"/>

Class
sub

[Signature]

9/27/07

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10828925
	Filing Date	2004-04-20
	First Named Inventor	Cappelletti
	Art Unit	1616 1618
	Examiner Name	to be assigned D. Jones
	Attorney Docket Number	57637-1380

If you wish to add additional Foreign Patent Document citation information please click the Add button			Add
NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1		<input type="checkbox"/>
If you wish to add additional non-patent literature document citation information please click the Add button			Add
EXAMINER SIGNATURE			
Examiner Signature			Date Considered 9/27/07
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
<small> ¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached. </small>			